Chronic neutrophilic #leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management
Including key revisions to diagnostic criteria from WHO-HAEM5 and ICC systems
Open access: doi.org/10.1002/ajh.27…
#leusm #hemepath #mpnsm

Descubre la esperanza en la lucha contra la leucemia células peludas. 💪✨ Conoce cómo la combinación de obinutuzumab y vemurafenib está transformando el panorama de tratamiento. 🩺🔬 

#Leucemia   #HCL #Lymsm #Leusm

Advancements and Challenges in the Treatment of #AML | American Society of Clinical Oncology Educational Book ascopubs.org/doi/10.1200/ EDBK_438662 #leusm #asco2024

Bone marrow #inflammation in haematological malignancies
nature.com/articles/s4157…
#MDSsm #MPNsm #leusm #MMsm

Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification
Free access: doi.org/10.1002/ajh.27…
#hemepath #leusm #AML

#HemeSeries : w/Nitin Jain we🗣️SoC for #CLL

- Fixed Rx vs BTKi
- Acala vs Zanu?
- Pirtobrutinib ✅

Full discussion:
- cancernetwork.com/treatment-algo…
- Oncbrothers.com/cll-algo-2024
- Also on the “Oncology Brothers” podcast

#Leusm #HemeTwitter #MedTwitter #OncTwitter CancerNetwork®

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial ashpublications.org/bloodadvances/…

➡️ No difference in OS

➡️ Oligoblastic AML had better response with Guadecitabine

#leusm #AML

Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia mdpi.com/2772528 #mdpihematolrep via MDPI #leusm #CLL

👉👉👉Honored to meet with Dr Carl June Carl June today on his visit to @mdacc !! Thanks 🙏 to Dr Carin Hagberg, MD & MD Anderson Cancer Center team #endcancer #leusm #lymsm #CARTCD19 #ImmunoOnc Nitin Jain Bill Wierda, MD, PhD

The goal of the S1925 trial is to find out if early treatment can help people with chronic #lymphocytic #leukemia ( #CLL ) or small lymphocytic #lymphoma (SLL) live longer and have a better quality of life. Learn more at SWOG.org/S1925. Or call 1-800-4-CANCER. #leusm

Just out, congratulations Alex Bataller
Outcomes and genetics of AML in first relapse.
#hemepath Haematologica #leusm
haematologica.org/article/view/h…

Lower relapse incidence with haploi vs matched sibling or unrelated donor HSCT for CBF-AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the The EBMT
doi.org/10.1002/ajh.27… #BMTsm #leusm

Sharing our commentary on a phase 2 Ven-aza maintenance trial in AML recently published in The Lancet Haematology by Bazinet and colleagues from MD Anderson Cancer Center.

Happy to work from afar with my friend Chyn Chua on this 1/2 🇦🇺🇲🇽 #Leusm
thelancet.com/journals/lanha…

#HemeSeries : This is the #Algorithm we have used during our discussion w/ Nitin Jain for #CLL

#HemeTwitter #OncTwitter #MedTwtitter #leusm #MedEd CancerNetwork® #OncEd OncoAlert Hem-Onc Fellows Network

Check out #MPM24 and my talk on 🎯 💊 in myeloid malignancies on 5/5/24 #leusm Mikkael A. Sekeres MD, MS Stephen D. Nimer, MD Taylor Lab UM Sylvester Comprehensive Cancer Center

Blood Dr after the talk on 🎯 therapies in Myeloid malignancies #MPM2024 Sylvester Comprehensive Cancer Center Thank you for the opportunity to showcase our leukemia group’s (@MikkaelSekeres Justin Watts MD ) clinical trials Carmen Calfa, MD Jon Trent, MD, PhD Dr. Estela Rodriguez #leusm #AMLsm

mdpi.com/2770954
Review on #transplant eligibility in #older pts with #AML ! #leusm Top Biomedical Science MedStar Georgetown Georgetown Hematology/Oncology Fellowship Georgetown Lombardi

Phase 2 of #ClinicalTrial EA9152 is now enrolling! This study is exploring a new treatment approach for patients with T-cell or B-cell #ALL that has come back or does not respond to treatment. Learn more here: bit.ly/EA9152 #leukemia #leusm

👉👉👉 #HOPLive24 #HemOnc Pulse || Naveen Pemmaraju, MD & Sanam Loghavi, MD صنم لغوی 🔬🧬 teaming up to discuss new meaningful clinical endpoints in Myelofibrosis before our session together later today on #UnansweredQuestions in #MPNSM #hemepath #leusm Heme Reports | chadi nabhan MD, MBA, FACP Ruben A. Mesa, MD Vincent Rajkumar

The approach of HMA plus VEN with or without BMT for all patients with AML ashpublications.org/hematology/art… #leusm